RxDoctor Payments Data

Harmeet Singh, MD

Nephrology · Burlington, NCNPI 1306866967

Payments from drug & device makers

$2,433in general payments, 2019–2025

Across 94 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$484
  • AstraZeneca$427
  • Bayer$243
  • Aurinia Pharma U.S., Inc.$219
  • Calliditas Therapeutics US Inc.$175
  • Otsuka America Pharmaceutical, Inc.$158
  • plus $727 from 14 others

What the payments were for

  • Food & beverage$2,30095%
  • Education$1335%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,433 in reported general payments places this provider in the 60th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$175,186
Medicare patients
280
Services billed
1,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol221$169,956
JardianceEmpagliflozin79$56,031
LokelmaSodium Zirconium Cyclosilicate15$13,442
VeltassaPatiromer Calcium Sorbitex15$7,607
Torsemide247$3,945
Calcitriol163$2,683
Irbesartan117$2,449
Sevelamer Carbonate18$2,411
Calcium Acetate37$1,599
Potassium Chloride51$1,384
Losartan Potassium127$1,310
Potassium Citrate ErPotassium Citrate13$1,283
Midodrine Hcl26$1,075
Hydralazine Hcl96$895
Furosemide159$878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$427$183,398236 claims
Boehringer IngelheimJardiance$18$56,03179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →